Simón Vidal
posted inLongevity
10 days ago

Rapamycin administration for the first 45 days of life and life expansion by 10% in mice

Anastasia Shindyapina,Yongmin Cho
Alaattin Kaya,Alexander Tyshkovskiy,José Castro,Amy Deik,Juozas Gordevicius,Jesse Poganik,Andrew Chan,Steve Horvath,Leonid Peshkin
+9 authors
,Vadim Gladyshev
Claim your profile to earn Research CoinRSC Coin
Science Advances
Sep 16, 2022
RSC Coin+50


Development is tightly connected to aging, but whether pharmacologically targeting development can extend life remains unknown. Here, we subjected genetically diverse UMHET3 mice to rapamycin for the first 45 days of life. The mice grew slower and remained smaller than controls for their entire lives. Their reproductive age was delayed without affecting offspring numbers. The treatment was sufficient to extend the median life span by 10%, with the strongest effect in males, and helped to preserve health as measured by frailty index scores, gait speed, and glucose and insulin tolerance tests. Mechanistically, the liver transcriptome and epigenome of treated mice were younger at the completion of treatment. Analogous to mice, rapamycin exposure during development robustly extended the life span of Daphnia magna and reduced its body size. Overall, the results demonstrate that short-term rapamycin treatment during development is a novel longevity intervention that acts by slowing down development and aging, suggesting that aging may be targeted already early in life.


Leave a comment or write a review